Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has shared an announcement.
Botanix Pharmaceuticals has notified the market that a total of 6.5 million options on issue have lapsed without being exercised. These include 2 million options expiring on 1 December 2025 with an exercise price of $0.195 and 4.5 million options expiring on 13 March 2026 with an exercise price of $0.078, resulting in a reduction of potential future share dilution for existing shareholders.
The cessation of these options simplifies Botanix’s capital structure by removing a block of unexercised convertible securities from its register. This change may marginally improve capital clarity for investors and indicates that prevailing market conditions did not support the conversion of these options into ordinary shares at their respective exercise prices.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Ltd is an Australian-listed biotechnology company focused on pharmaceutical development. The company operates in the pharmaceuticals industry and its securities trade on the ASX under the ticker BOT, with various classes of options forming part of its capital structure.
Average Trading Volume: 15,652,456
Technical Sentiment Signal: Sell
Current Market Cap: A$94.92M
For a thorough assessment of BOT stock, go to TipRanks’ Stock Analysis page.